2.90Open2.90Pre Close0 Volume71 Open Interest22.50Strike Price0.00Turnover100.18%IV12.29%PremiumJan 17, 2025Expiry Date0.12Intrinsic Value100Multiplier23DDays to Expiry2.78Extrinsic Value100Contract SizeAmericanOptions Type0.5628Delta0.0692Gamma9.63Leverage Ratio-0.0504Theta0.0066Rho5.42Eff Leverage0.0224Vega
Neurogene Stock Discussion
This Will continue to drive downward. And after you finally sell your position for a loss, they will buy back. Follow the money
📊⚡️📊
NEWS
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be ...
No comment yet